
OPIOID PRESCRIBING PRACTICES

ALGORITHM 1. Opioid Prescribing Decision Making





ALGORITHM 2. Weaning Patients Off Patient Controlled Analgesia (PCA), Caregiver Controlled Analgesia (CCA), or Nurse Controlled Analgesia (NCA)






TABLE OF CONTENTS Algorithm 1. Opioid Prescribing Decision Making Algorithm 2. Weaning Patients Off Patient Controlled Analgesia (PCA), Caregiver Controlled, or Nurse **Controlled Analgesia Target Population Background | Definitions** Colorado's Legislative Response (Senate Bill 22) **Initial Evaluation** Step 1. Assess Pain Step 2. Assess Sufficiency of Non-Opioid Analgesia Step 3. Assess Risk **Clinical Management** Prescribing Decision-Making If Discharge Opioid Analgesics are Indicated Non-Pharmacologic Interventions | Multimodal Approach to Pain Management Titration Weaning Plan and Recommendations Parent | Caregiver Education **Related Documents** References Appendix A. Opioid Prescribing Table Appendix B. The CRAFFT Screening Interview (version 2.0) Appendix C. Colorado Prescription Drug Monitoring Program Login Information Appendix D. Substance Abuse Resources Clinical Improvement Team

TARGET POPULATION

Inclusion Criteria

• ED/UC patients, inpatients, and outpatients with acute pain

Exclusion Criteria

- Patients with chronic pain or existing chronic opioid prescription
- Patients with cancer
- Bone marrow transplant (BMT) patients
- Patients with sickle cell disease
- Patients of the Center for Cancer and Blood Disorders (CCBD)
- ICU Patients
- Hospice and palliative care patients



BACKGROUND | DEFINITIONS

Overview of the Opioid Crisis in the United States

- Prior concern about undertreating pain led to a move to address pain as the "fifth vital sign" in the late 1990s.
- In part because of that change in practice, opioid prescriptions in the United States skyrocketed between 1999 and 2010, including to the adolescent and young adult populations¹. Rates of opioid prescribing to adolescents and young adults nearly doubled between 1994 and 2007¹.
- The increase in opioid prescribing over the last few decades has been associated with an increase in the rates
 of opioid misuse and abuse. In 2012, 12.5 million Americans reported abuse of prescription opioids, up from 4.9
 million in 1992. Younger age (18-25 years) is associated with an increased risk of abuse. Between 13-31% of
 adolescents and young adults have reported lifetime nonmedical use of prescription medications¹.
- Recent research has identified a link between the duration of an initial opioid prescription and long-term use. In a sample of opioid-naïve, cancer-free adults, an initial opioid prescription lasting three or more days significantly increased the likelihood of chronic opioid use, with the sharpest increase in risk for chronic use occurring after the 5th and 31st days². Given this correlation, <u>new CDC guidelines recommend that opioid prescriptions for adults with acute pain should be limited to the shortest possible duration. The CDC specifically recommends prescribing fewer than 7 days (and, for most patients, fewer than 3 days) of opioids when initiating acute pain treatment³.
 </u>
- Given the national context of the opioid crisis, pediatric health care providers face four interrelated concerns⁴:

1) Risk of unintentional opioid poisoning in children

- Over 22,000 children were treated in US emergency departments for opioid poisoning between 2006 and 2012⁵.
- o Children can experience life-threatening complications with exposures to even low doses of opioids.
- 2) Risk that legitimate use of opioid prescriptions may contribute to non-medical use or abuse among adolescents and young adults
- Nearly 80% of new heroin users have previously used opioid pain medications⁶.
- Children and adolescents who report "legitimate" use of prescription opioids prior to 12th grade are 33% more likely to misuse opioids as compared to those who had never used any prescription opioids⁷.

3) Risk of diversion of unused prescription opioids

- A high percentage of opioids dispensed to children go unused, further increasing the risk for accidental poisoning, diversion, and misuse⁸.
- 4) A paucity of evidence to inform opioid prescribing practices for pediatric populations, which may contribute to over- or under-prescribing of opioid analgesics.
- In the absence of pediatric-specific research and recommendations, prescribers must rely on clinical judgement, expert consensus, and adult-focused guidelines and studies.


Colorado's Legislative Response (Senate Bill 22)

- In May 2018, Governor John Hickenlooper signed into law Senate Bill 18-22 Clinical Practice for Opioid Prescribing. This new law limits outpatient opioid prescriptions for patients meeting certain criteria to a 7 days' supply. Please <u>click here for more information</u> about this law.
- The legislation requires prescribers or their delegates to check the <u>Colorado Prescription Drug Monitoring</u> <u>Program database</u> prior to prescribing a second opioid prescription for certain patients.
- The law applies to physicians, physician assistants, advanced practice nurses with prescribing authority, podiatrists, optometrists, dentists, and veterinarians.



Key Drivers for Addressing the Opioid Crisis

The Institute for Healthcare Improvement's (IHI) Innovation Report on Addressing the Opioid Crisis in the United States (2016)⁹ outlined four key drivers for reducing the opioid crisis, as depicted in the diagram below:



This clinical pathway aims to provide guidance to CHCO providers and other care team members regarding the first two drivers: *limiting the supply of opioids* and *raising awareness of the risk of opioid addiction* among health care providers, patients, and families. As such, the clinical pathway aims to integrate the best available evidence and expert consensus to inform opioid prescribing practices, effective pain management, and patient/family education on safe opioid use, storage, and disposal.

Definitions

Addiction- Primary, chronic, neurobiological disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving¹⁰.

Diversion – Any act or deviation that removes a prescription drug from its intended path from the manufacturer to the patient for which it was prescribed.



Equianalgesic dose – The dose at which two opioids (at steady state) provide approximately the same pain relief. Most tables are derived from single-dose studies and cannot fully address all clinical factors so must be used with caution¹¹.

Hyperalgesia – State of nociceptive sensitization caused by exposure to opioids. The condition is characterized by a paradoxical response whereby a patient receiving opioids for the treatment of pain could become more sensitive to certain painful stimuli¹².

latrogenic Withdrawal - latrogenic withdrawal occurs when opioid analgesic and sedating medications are stopped abruptly or weaned too rapidly, causing central nervous system hyperirritability, autonomic system dysregulation, gastrointestinal dysfunction and motor abnormalities. Factors associated with increased risk for withdrawal: younger age, pre-existing cognitive impairment, higher pre-weaning daily opioid requirement, or three or more pre-weaning sedative medications¹³.

Incomplete cross tolerance – The development of tolerance to the effects of other structurally similar drugs in the same pharmacologic class after long term exposure. This effect is rarely complete in opioids.

Opioid analgesic – Act by binding to specific receptors of the µ and K types in the central and peripheral nervous systems. Narcotic analgesic derived at least in part synthetically.

Physical dependence – State of adaptation manifested by a drug class-specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood levels of the drug, and/or administration of an antagonist¹⁰.

Tolerance - State of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug's effects over time. It is the development of a need to increase the dose of an opioid agonist to achieve the same analgesic (or sedative) effect previously achieved with a lower dose. Rotating opioids can be helpful in preventing the need to continuously increase doses due to incomplete cross tolerance. NOTE: tolerance to the constipating effects rarely occurs¹³.

WAT-1 - Withdrawal assessment tool. An assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients¹⁴.

Weaning - Decreasing the dose of opioid or sedating medication over time rather than abruptly discontinuing the medication to minimize withdrawal.

Opioid Types and Administration Routes


• Refer to Appendix A. Opioid Prescribing Table

Characteristics and Pharmacogenomics of Opioid Therapy

Desirable characteristics	Undesirable characteristics	Pharmacogenomics		
 Analgesia for somatic and visceral pain Anxiolytic Euphoria effects 	 Nausea/vomiting Respiratory depressant Constipation Urinary Retention Pruritus Dysphoria Cough suppression 	 Genetic factors may alter: Perception of pain Pharmacokinetic mechanisms making active drug available at site of action Pharmacodynamic interaction of drug and intended target receptor Metabolism and absorption of drugs 		



Diversion Risk by Type of Opioid



Note: Diversion risk changes frequently.

Natural and semi-synthetic = morphine and codeine are natural; oxycodone, hydrocodone, hydromorphone, and oxymorphone are semi-synthetic

Synthetic = fentanyl and tramadol. Fentanyl is a synthetic opioid that is legally made as a pharmaceutical drug to treat pain, or illegally made as a non-prescription drug and is increasingly used to intensify the effects (or "high") of other drugs, such as heroin.

Non-Opioid Therapy

Non-opioid therapy	Benefits	Cautions/Risks
Acetaminophen	 Tried and true Scheduled is good Consider IV in special cases (Refer to <u>Lexicomp</u> for CHCO restrictions) 	 Watch maximum daily doses: <u>Lexicomp</u> Avoid acetaminophen containing opioid concoctions (keep it simple)
AnticonvulsantsGabapentinPregabalin	 Stabilizes alpha-2-delta subunit of voltage dependent calcium channel Not metabolized, few drug interactions Significant anti-anxiety effects Helpful for neuropathic pain when used at high doses 	 Dose reduction necessary for renal dysfunction Sedating, may cause ataxia, titrate slowly Takes time to work Delays in processing of information



 NMDA receptor antagonist Ketamine 	 Can have excellent analgesic efficacy at subanesthetic doses Can be maintained as an infusion Opioid sparing and may assist in the prevention of tolerance 	 Must consult Acute Pain Service for use on medical floors May cause vivid nightmares and hallucinations
 NSAIDs Ibuprofen Ketorolac Naproxen Celecoxib Aspirin (not used for pain in pediatric patients) 	 Analgesic Antipyretic Anti-inflammatory 	 GI tract problems Renal toxicity Platelet inhibition Hypersensitivity
 Benzodiazepines Clonazepam Diazepam Lorazepam Midazolam 	 Muscle relaxant/antispasmodic Anxiolytic 	 Sedating Can cause respiratory depression when combined with opioids – use caution Does not work directly for visceral pain
Muscle Relaxants* • Baclofen • Benzodiazepines • Cyclobenzaprine Local Anesthetics • Lidocaine patch • Lidocaine gel	 Diazepam often used for post- operative muscle spasms Baclofen used for spasticity related to spinal cord injuries Topical option for patients with localized pain Can use if NPO Lidocaine patch can be cut 	 Sedation and CNS depression – especially when combined with opioids Titrate slowly Watch maximum doses: <u>Lexicomp</u>

*Alternative options exist but are non-formulary at CHCO.

Alternatives to Opioids (ALTOs) in the Emergency Department*

Specific alternatives to opioids (ALTOs) can be used in the ED setting for musculoskeletal pain and abdominal pain.

First line agents are bolded and highlighted in yellow. Please refer to LexiComp for dosing and administration.

	Musculoskeletal Pain								
Medication	Route	Pearls							
Acetaminophen	PO, PR, IV	AntipyreticDosing may vary based on route of administration.							
lbuprofen	PO	Antipyretic, anti-inflammatoryDo not give in combination with other NSAIDs							
Ketorolac	IV PO	 Antipyretic, anti-inflammatory Therapy should be limited to 48 hours Do not give in combination with other NSAIDs 							
Naproxen	PO	Antipyretic, anti-inflammatoryDo not give in combination with other NSAIDs							
Lidocaine	Topical	 Dosing based on weight and BSA Multiple patches may be used simultaneously- see formulary for specific recommendations 							
Capsaicin	Topical	Apply 3-4 times a dayDo not use on wounds or broken skin							
Diazepam	PO, IV	Great for musculoskeletal spasms or anxiolysisMay also consider other benzodiazepines							



	Abdominal Pain								
Medication	Route	Pearls							
Metoclopramide	PO, IV, IM	• Caution with extrapyramidal side effects (can give diphenhydramine to decrease EPS and for additive effect)							
Diphenhydramine	PO, IV	SedatingIV and PO dosing is the same							
Prochlorperazine	PO, PR, IM, IV	 Sedating Caution with extrapyramidal side effects; may give with diphenhydramine to reduce risk 							
Dicyclomine	PO	 Anticholinergic side effects, usually dose limiting Should not be used in infants less than 6 months 							
Cyproheptadine	PO	Well tolerated, may be sedating							
Promethazine	PO, IV, IM	IV, IM, and PO dosing is the same							
<u>Hyoscyamine</u>	PO	May cause anticholinergic side effects							
<u>Haloperidol</u>	PO, IV	 Useful in cannabinoid hyperemesis syndrome Avoid in children < 3 years old or psychiatric patients 							
<u>Capsaicin</u>	Topical	 Apply 3-4 times a day Do not use on wounds or broken skin May be helpful for cannabinoid hyperemesis syndrome when applied to abdomen 							

*Not all agents listed are available at each CHCO ED location.

INITIAL EVALUATION

Step 1. Assess Pain

Please refer to the Pain Assessment and Management Policy.

Step 2. Assess Sufficiency of Non-Opioid Analgesia

For patients experiencing acute pain, are alternatives to opioids (e.g., APAP, NSAIDs, heat, ice, immobilization, etc.) sufficient?

- If YES, continue with scheduled, <u>non-opioid medications</u> and/or <u>non-pharmacologic/multi-modal therapy</u> and ensure education on safe pain medication schedule and list.
- If NO, continue to step 3.

Step 3. Assess Risk

Providers should conduct (or review the results of) a multi-faceted risk assessment prior to prescribing opioid medications to identify patients who may be at high risk for misuse or addiction. This should include assessing risk in the family/home environment and, for adolescents, personal risk for substance use/misuse.

A. Assessing risk in the family/home environment

The following are established family/home risk factors that may increase risk for misuse, abuse, or diversion¹⁵. **Providers are advised to discuss the following questions with parents/caregivers and document the discussion in Epic in a progress note.**

- Current or prior substance misuse/abuse by family members [from CHCO's Social Screener; To be asked of parent/caregiver]
 - Do you or anyone else in your home have a problem with alcohol or marijuana?



• Do you or anyone else in your home use medicine not prescribed to you, or any other type of drugs (such as cocaine, heroin or meth)?

If the caregiver/parent responds "yes" to one or both questions, the patient is considered at <u>moderate/high</u> risk for opioid misuse.

If under 18, does the patient live with a responsible adult parent or guardian?

If a patient under 18 does not live with at least one parent or guardian (e.g., homeless or emancipated minor), the patient may be considered at <u>moderate/high risk</u> for opioid misuse.

B. Assessing risk among adolescent patients: The CRAFFT © Screening Interview – INPATIENT ONLY

The CRAFFT © is a brief behavioral health screening tool developed and validated for screening adolescents and young adults age 12-18 for substance use disorders¹⁶⁻¹⁹. The three-question pre-screen and six-question tool are designed to determine whether further assessment and conversation around substance use and risks is warranted. The CRAFFT © is recommended by American Academy of Pediatrics' Committee on Substance Abuse.

The CRAFFT (version 2.0) © Screening Interview is integrated in the inpatient nursing admissions database in Epic. To view the screening questions, <u>please click here</u> or <u>refer to Appendix B</u>. To access the CRAFFT (version 2.0) © in languages other than English, <u>please click here</u>.

Two or more YES answers on any of the nine CRAFFT © questions indicate that the patient is considered at moderate/high risk for opioid misuse.

CLINICAL MANAGEMENT

Prescribing Decision-Making

Note: ED/UC providers may not provide replacement prescriptions for opioids that are lost, destroyed or stolen.

All Patients Regardless of Risk Category:

- Proceed with cautious use and prescription of opioid therapy, limiting the amount prescribed while ensuring pain management. Refer to <u>Appendix A.</u> for recommended drugs, doses, etc.
- No long acting opioids may be prescribed in the ED/UC. It is recommended to avoid long acting opioids in inpatient, surgical, and outpatient settings as well.
- Ensure pain is listed on the problem list and document the pain management plan in Epic.
- Recommend use of non-pharmacologic and multi-modal approaches to pain management.
- If pharmacogenomic testing is available or has been completed, it should be considered for all patients.
- Discuss goals and expectations for pain management (for example, patient may not be pain free).

Moderate/High Risk Patients:

Risk stratification should not be used to deny pain treatment. <u>Consider</u> the following options/resources prior to prescribing opioid therapy:

- Discussing concern with patient and/or caregiver
- Consulting with Social Work for additional assessment
- Consulting with the Acute Pain Service
- Checking the Colorado Prescription Drug Monitoring Program Website
 - The <u>Colorado Prescription Drug Monitoring Program</u> (PDMP) is an electronic database that tracks prescriptions for controlled substances dispensed by registered pharmacies in Colorado. Information found



can include patient identification, prescription characteristics (type, quantity, etc.), prescriber, pharmacy, payer source, and date prescribed.

- Colorado licensed individuals can register to access the PDMP, including: Physicians, Dentists, PAs, NPs, Pharmacists, and Resident/Fellow Physicians. Prescribers and pharmacists to authorize up to three delegates to access the PDMP for their patients. <u>Please refer to these FAQs for more information about</u> <u>authorizing delegates</u>.
- The State of Colorado and the CDC recommend that prescribers (or their delegate) check the PDMP prior to prescribing an opioid medication^{20, 21}. The CDC notes that using the PDMP is a promising intervention to identify individuals who may be at high-risk for misuse and who may benefit from intervention^{20, 21}.
- As of May 2018, Senate Bill 18-22 <u>REQUIRES</u> that prescribers (or their delegate) check the PDMP registry before prescribing a refill or second outpatient prescription for certain patients. Please <u>click here for more</u> <u>information</u> about this requirement.
- o To register with or access the Colorado PDMP, visit this website.
- For further information, please refer to Appendix C.

If one or more of the following characteristics are found in the PDMP, the patient is considered at <u>moderate/high risk</u> for opioid misuse:

- Multiple (> 2) opioid prescriptions in a short time interval (within past 6 months)
- Multiple providers (>2) prescribing an opioid
- Multiple pharmacies (>2) dispensing an opioid
- Large amount prescribed (duration > 7 days)

If a provider identifies concerns in the PDMP, it is advised to address them with the patient and/or parent/caregiver. The following are suggestions to guide that conversation:

- Normalize the conversation and set the stage with example language such as: "I review the state's
 prescription drug monitoring program database so I can ensure I understand everything you are taking"
- Identify any areas of concern and discuss them with the patient and/or caregiver/family: "Something I saw in the database concerned me. Can you tell me more about ____?"; "Can you help me understand why you are getting prescriptions from so many providers/pharmacies?"
- **Document** any PDMP concerns and the discussion in Epic in a progress note.
- Consulting with patient's primary care provider
- Obtaining both a standard urine toxicology screen (for immediate results), and expanded panel (pain clinic monitoring profile) to assess for drug abuse/misuse prior to opioid administration. If positive, strongly consider alternative therapies. However, if patient continues to need opioid therapy, strict follow up and limited prescribing is essential. Follow up of the expanded panel will be required by PCP, or managing specialty to evaluate the concern for misuse as an outpatient.
- Extending hospital stay for duration of opioid therapy, ensuring discussion with case management and documentation of rationale for an extended stay.
- Referring to substance abuse treatment center and communication with PCP or managing specialty about the referral.
- If patient has history of addiction or overdose, consider prescribing <u>intranasal naloxone</u>. Refer to pediatric administration guidelines for dosing.
 - o Intranasal naloxone is available at Walgreens at CHCO location
 - For other pharmacies: <u>http://stoptheclockcolorado.org/</u>
 - Additional educational videos pertaining to naloxone standing orders and intranasal administration: <u>https://prescribetoprevent.org/patient-education/videos</u>



If Discharge Opioid Analgesics Are Indicated

- Colorado law requires providers to <u>limit outpatient opioid prescriptions</u> for patients meeting certain criteria to <u>a 7-day supply</u>. <u>Click here for more information</u>.
- Prescribe short-acting opioids only. Refer to PO-IR formulations listed in Appendix A.
- Recommend use of non-pharmacologic and multi-modal approaches to pain management.
- Refer to the Parent | Caregiver Education section below for key points to discuss.
- Refer to Appendix A. for recommended drugs, doses, duration, etc.
- <u>ED/UC setting</u>: Recommend limiting discharge prescriptions to a <u>maximum of 3 days</u>. Advise patients with
 persistent pain to follow-up with PCP or sub-specialist for re-evaluation.
- Inpatient setting: Recommend limiting discharge prescriptions to a maximum of 7 days. If the patient/family screened moderate/high risk for substance use OR if on-going (> 7 days) acute pain is likely:
 - Ensure verbal communication with PCP prior to discharge.
 - Ensure PCP or sub-specialist follow-up appointment is scheduled within 7 days.
- <u>Ambulatory setting</u>: Recommend limiting outpatient prescriptions to a <u>maximum of 3 to 7 days</u>, depending on condition and diagnosis. If the patient/family screened moderate/high risk for substance use **OR** if on-going (> 7 days) acute pain is likely, ensure PCP or sub-specialist follow-up appointment is scheduled within 7 days.
 - As of May 2018, Senate Bill 18-22 <u>REQUIRES</u> that prescribers (or their delegate) check the Prescription Drug Monitoring Program (PDMP) registry before prescribing a refill or second outpatient prescription for certain patients. Please <u>click here for more information</u> about this requirement.

Non-Pharmacologic Interventions | Multimodal Approach to Pain Management

Opioid therapy <u>must</u> be accompanied by non-pharmacologic interventions to ensure a multi-modal approach to pain management. A multi-modal approach:

- Uses multiple methods to achieve highest patient and family satisfaction
- Hits multiple targets
- Minimizes side effects and toxicity
- Maximizes function

Consider the following non-pharmacologic interventions by age and type of pain:

Infants and young children	Older children and adolescents
 Non-nutritive sucking (with sugar water) – refer to the <u>Sucrose Analgesia in the Infant</u> policy Swaddling and tucking Massage Environment modification Rocking Video distraction Structured non-parent involvement 	 Movement/Exercise Positioning Temperature therapy Preparation/Education/Information Coping skills training* Parent training/modeling positive coping behaviors * Distraction Relaxation Imagery (English version) Desensitization Positive reinforcement/verbal praise Education/information Hypnosis* Biofeedback* Cognitive Behavioral Therapy* Mindfulness* Medical Meditation*

*Requires an Epic consult to child life, C/L psychology, or pain psychology

Please view this brief Altitude Video for more information on multimodal analgesia.



Titration

- "Turning off" at the end of a dose period typically requires increasing the dose, not the frequency.
- When you need to titrate up, typically increase dose by 10-20%, and then wait 2-3 doses before increasing again.
- Always go back to the question "Do I have a good non-opioid baseline ensuring around the clock multimodal analgesia when appropriate, considering the risks and benefits?"
- Start low and go up carefully in patients with sleep disordered breathing, sleep apnea, or significant neuromuscular disease.
- Consider switching opioid agents if no analgesic benefit is obtained after multiple titrations.

Consult with Pharmacy and/or the Acute Pain Service for further guidance.

Weaning Plan and Recommendations

Note: The ICUs are excluded from the scope of this clinical pathway. For PICU patients, please refer to the Ready For Extubation and Weaning Pathway.

latrogenic withdrawal occurs when opioid analgesic and sedating medications are stopped abruptly or weaned too rapidly, causing central nervous system hyperirritability, autonomic system dysregulation, gastrointestinal dysfunction and motor abnormalities. The information in this section and the related algorithm is intended to minimize opioid withdrawal by guiding weaning of opioids and benzodiazepines in patients that are at risk for withdrawal.

Refer to Algorithm 2. Weaning Patients Off Patient Controlled Analgesia (PCA), Caregiver Controlled, or Nurse Controlled Analgesia.

Withdrawal Assessment Tool (WAT-1)

The **Withdrawal Assessment Tool (WAT-1)** is a standardized assessment tool of iatrogenic withdrawal syndrome from weaning off opioids and benzodiazepines in hospitalized term infants and pediatric patients. The WAT-1 is integrated in Epic and should be used with:

- Any term or older NICU patient who has received continuous infusion sedation/pain medications for longer than 5 days and is now weaning.
- Patient transitioned to oral methadone/lorazepam/clonidine, due to weaning off medications given in the hospital.

<u>Please click here</u> for more information about the WAT-1.

Weaning Considerations

- <u>NOTE:</u> these recommendations DO NOT include long acting opioids. For assistance prescribing and weaning extended release opioids and methadone, please contact Acute Pain Service (APS) – extension x75433.
- The criteria for weaning a patient to oral medication includes:
 - o Bowel sounds, tolerance of liquid foods, and advancing without problems to solids
 - Self-administered (demand dose) medication attempts/doses delivered and pain scores are trending down (or observed functionality of the patient if clinically improving)
- **NOTE:** Make sure patient is receiving multimodal therapy for pain management [acetaminophen + ibuprofen (consider scheduling) + PCA].
- All patients weaning off opioids should have a <u>Withdrawal Assessment Tool (WAT-1)</u> score ordered as well.
- Once a wean is created, it should be documented in the patient's medical record and communicated to the family. Once the patient is tolerating the wean and the plan is finalized, a calendar should be given to the family along with the signs and symptoms of withdrawal patient handout.

- Children's Hospital Colorado
- Use for patients currently on scheduled opioids that need to wean off that are greater than 90 days old (for example: patients transferring from the Intensive Care Unit (ICU) who have been on continuous infusion opioids)
- Wean one medication at a time (example: wean oxycodone completely off and then wean benzodiazepine and then clonidine if applicable)
- Consider incomplete cross tolerance when converting from IV to PO opioids and reduce the oral dose by 20-50% in initially
- If weaning a patient on a Patient Controlled Analgesia (PCA) wean all components (continuous rate, demand dose, and clinician bolus) by the same amount (for example, wean all components by 20% every 24 hours)
- In general, wean 10-20% from original total daily dose every 24 hours and adjust wean as needed
- CONTINUE WEAN:
 - Withdrawal Assessment Tool (WAT) scores are less than 4 for 24 hours continue current wean plan
 - Wean to lowest ending dose (see table below) scheduled every 4 hours then consider every 6-hour schedule once at lowest ending dose. Once at every 6 hours, next step is PRN (as needed). Follow WAT scores for 72 hours.
- ADJUST WEAN:
 - If WAT scores are 4 or greater or patient having breakthrough pain, then nurse to give breakthrough dose of agent ordered (50% of scheduled dose).
 - If more than 2 breakthrough doses are required in 24-hour period, then slow wean (recommendations as follows):
 - If weaning patient by 20% every 24 hours, hold wean for 24 hours and restart by weaning 10% every 24 hours
 - If weaning patient by 10% every 24 hours, hold wean for 24 hours and restart by weaning 10% every 48 hours
 - If weaning patient by 20% every 48 hours, hold wean for 24 hours and restart by weaning 10% every 48 hours
 - If weaning patient by 10% every 48 hours, hold wean for 24 hours and restart by weaning 10% every 72 hours

LOWEST ENDING DOSE WHEN WEANING MEDICATIONS (intermittent dosing only)										
Medication	Lowest Ending Dose mg/kg PO (less than 50kg)	Lowest Ending Dose mg PO (50kg or greater)	Lowest Ending Dose mg/kg IV (less than 50kg)	Lowest Ending Dose mg IV (50kg or greater)						
Morphine	0.1mg/kg/dose PO	5mg PO	0.05mg/kg/dose IV	2mg IV						
OxyCODONE	0.05mg/kg/dose PO	2.5mg PO	N/A	N/A						
HYDROmorphone	0.03mg/kg/dose PO	1mg PO	0.005mg/kg/dose IV	0.25mg IV						
Methadone	0.05mg/kg/dose PO	2.5mg PO	0.05mg/kg/dose IV	2mg IV						
DiazePAM	0.05mg/kg/dose PO	2mg PO	0.05mg/kg/dose IV	2mg IV						
LORazepam	0.05mg/kg/dose PO	2mg PO	0.05mg/kg/dose IV	2mg IV						



PARENT | CAREGIVER EDUCATION

The following education topics should be discussed with parents/caregivers prior to prescribing opioid medications:

- 1. Benefits of opioid use, including:
 - o Increase function and mobility for participation in activities of daily living
 - o Pain relief
 - Modulates body's stress response
- 2. Risks of opioid use, including:
 - Acetaminophen (APAP)-containing products
 - o Interactions with other medications and substances
 - Adverse side effects: sedation and respiratory depression, constipation, nausea and vomiting, itching, cognitive impairment, urinary retention
 - o Potential for misuse (including diversion and abuse)
 - Importance of taking medications as directed
- 3. Risk of diversion:
 - o Opioid prescriptions are intended for patient only, not for anyone else.
 - Safe storage
 - Keep in child resistant packaging.
 - Store package in a secure, locked location.
 - <u>Refer to this brochure for more information</u>.
 - Safe disposal of unused medications
 - There is a green medication take-back box located at the main entrance of the Children's Hospital Colorado Anschutz campus just past the reception desk. This take-back box can be used to dispose of any over-the-counter or prescription medicines.
 - <u>Click here for the FDA's guidance</u> on safe disposal of unused medications, including the list of medications that can be flushed.
 - <u>Click here for the EPAs guidance</u> on safe disposal.
 - View a list of <u>authorized collectors by zip code here</u> or call the DEA Office of Diversion Control at 1-800-882-9539 to find your nearest location.
- 4. Support/getting help:
 - Consult social work if the risk screening process indicates a patient is at moderate to high risk of opioid misuse.
 - Refer to Appendix D for community-based substance abuse resources.
- 5. Review and, as necessary, provide guidance on multimodal analgesia and weaning.
- 6. Review criteria for when to seek follow-up if pain persists.
- 7. Review bowel regimen.
- 8. Consider providing the following patient/caregiver handouts:
 - Opioid Medicine: <u>English</u> and <u>Spanish</u>
 - Helping pain after surgery: English and Spanish
 - Guided Breathing and Imagery Script: Ways to help your Child to Relax and Relieve Pain: <u>English</u> and <u>Spanish</u>



- o Distraction, Relaxation and Imagery: English and Spanish
- What is Opioid Withdrawal Syndrome?: <u>English</u> and <u>Spanish</u>
- o Additional pain management topics and languages available here.

RELATED DOCUMENTS

CHCO Policies and Procedures:

- Pain Assessment and Management
- Pain Management: Intravenous Patient Controlled Analgesia (IV PCA) Set-Up, Administration and Documentation
- Investigating and Reporting Drug Diversion

Colorado Policies & Resources:

- <u>Colorado Senate Bill 18-22 Clinical Practice for Opioid Prescribing</u>
- <u>Colorado Department of Regulatory Affairs (DORA) Policy for Prescribing and Dispensing Opioids</u>
- <u>Colorado Department of Health Care Policy and Financing (HCPF): Opioid Policy Update: FAQs for Providers</u>
- Colorado Department of Health Care Policy and Financing (HCPF): Opioid Policy Update: FAQs for Members
- <u>Colorado Prescription Drug Monitoring Program</u>
- <u>The Colorado Consortium for Prescription Drug Abuse Prevention</u>
- <u>Colorado Department of Public Health and Environment (CDPHE) Opioid Overdose Prevention</u>

National Resources:

• <u>Centers for Disease Control and Prevention Guideline for Prescribing Opioids for Chronic Pain</u> (Note: Refer to Recommendation 6 for guidance related to opioids prescribing for acute pain)

REFERENCES

- 1. Fortuna RJ, Robbins BW, Caiola E, Joynt M, Halterman JS. Prescribing of controlled medications to adolescents and young adults in the United States. *Pediatrics* 2010;126(6):1108-1116.
- Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use- United States, 2006-2015. *MMWR Morb Mortal Wkly Rep* 2017;66:265–269. DOI: http://dx.doi.org/10.15585/mmwr.mm6610a1.
- 3. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain United States, 2016. *Jama.* 2016;315(15):1624-1645. Doi:10.1001/jama.2016.1464.
- 4. Schechter, N. Pediatric pain management and opioids: The baby and the bathwater. *JAMA Pediatr.* 2014;168(11):987-988. doi:10.1001/jamapediatrics.2014.1441
- 5. Tadros A, Layman SM, Davis SM, Bozeman R, Davidov DM. Emergency department visits by pediatric patients for poisoning by prescription opioids. *Am J Drug Alcohol Abuse* 2016; 42(5):550–555.
- 6. Muhuri PK, Gfroerer JC, Davies MC. CBHSQ data review: associations of nonmedical pain reliever use and initiation of heroin use in the United States. *Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration;* August 2013. Available at:



www.Samhsa.gov/data/sites/default/files/DR006/DR006/nonmedicalpain-reliever-use-2013.htm. Accessed May 17, 2017.

- 7. Meich R, Johnston L, O'Malley PM, Keyes KM, Heard K. Prescription Opioids in Adolescence and Future Opioid Misuse. *Pediatrics* 2015:136(5). DOI: 10.1542/peds.2015-1364,
- 8. Abou-Karam M, Dubé S, Kvann HS, et al. Parental report of morphine use at home after pediatric surgery..*J Pediatr* 2015;167(3):599-604.
- 9. Martin L, Laderman M, Hyatt J, Krueger J. Addressing the Opioid Crisis in the United States. *IHI Innovation Report.* Cambridge, Massachusetts: Institute for Healthcare Improvement; April 2016.
- 10. Savage S, Covington E, Heit H, et al. *Definitions Related to the Use of Opioids for the Treatment of Pain: A consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine*. Glenview, IL: AAPM; 2011.
- 11. Shaheen PE, Walsh D, Lasheen W, et al. Opioid equianalgesic tables: are they all equally dangerous? *J Pain Symptom Manage*. 2009 Sept;38(3): 409-17.
- 12. Lee M, Silverman S, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. *Pain Physician*. 2011; 14:145-161.
- 13. Galinkin J, Koh JL. Recognition and management of iatrogenically induced opioid dependence and withdrawal in children. *Pediatrics.* 2014 Jan;133(1):152-5.
- Franck LS, Harris SK, Soetenga DJ, et al. The Withdrawal Assessment Tool Version 1 (WAT-1): an assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients. *Pediatr Crit Care Med*. 2008 Nov;9(6):573–80.
- 15. McHugh RK, Nielsen S, Weiss RD. Prescription drug abuse: from epidemiology to public policy. *J Subst Abuse Treat.* 2015; 48:1–7. [PubMed: 25239857]
- 16. Knight JR, Shrier LA, Bravender TD, Farrell M, Vander Bilt J, Shaffer HJ. A New Brief Screen for Adolescent Substance Abuse. *Archives of Pedaitric Adolescent Medicine* 1999; 153:591-596.
- 17. Knight JR, Sherritt L, Shrier LA, Harris SK, Chang G. Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. *Arch Pediatr Adolesc Med* 2002;156(6):607-14.
- 18. Knight JR, Sherritt L, Harris SK, Gates EC, Chang G. Validity of brief alcohol screening tests among adolescents: A comparison of the AUDIT, POSIT, CAGE and CRAFFT. *Alcohol Clin Exp Res* 2002;27:67-73.
- 19. Levy S, Sherritt L, Harris SK, Gates EC, Holder DW, Kulig JW, Knight JR. Test-retest reliability of adolescents' self-report of substance use. *Alcohol Clin Exp Res* 2004;28:1236-41.
- 20. Colorado Department of Regulatory Agencies. About the PDMP Program. Available at: <u>https://www.colorado.gov/dora-pdmp</u>. Accessed September 12, 2017.
- Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. What healthcare providers need to know about PDMPs. Available at: <u>https://www.cdc.gov/drugoverdose/pdmp/providers.html</u>. Accessed August 20, 2017.



APPENDIX A. OPIOID PRESCRIBING TABLE

IR = immediate release **ER** = extended release. In ER forms, it takes 3-5 half lives of the medication to reach steady blood level

IV = intravenous; PO = oral; IT = intrathecal

*This table should only be used to determine the morphine equivalent dose and should NOT be used to determine doses when converting a patient from one opioid to another. For assistance in converting a patient from one opioid to another, please contact Pain Management Service or your floor pharmacist.

The Morphine Equivalent Dose (MED) Conversion Factor is derived from the Department of Health and Human Services (DHHS) Centers for Medicare and Medicaid Services (CMS) "Opioid Morphine Equivalent Conversion Factors" table. Available at https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Opioid-Morphine-EQ-Conversion-Factors-March-2015.pdf

An MED calculator is also available here: http://www.agencymeddirectors.wa.gov/Calculator/DoseCalculator.htm

Drug	Dosing/ Dosage Forms	Route	Onset	Peak Effect	Half-life	Duration	Morphine Equivalent Dose (MED) Conversion Factor*	Comments	Estimated cash price at Walgreens (2016)
fentaNYL	http://online.le xi.com/lco/acti on/doc/retriev	IV	1-3 minute s	5-10 minut es	5 mo-4.5yr: 2.4 hours Adults: 2-4 hours	30-60 minutes			
	e/docid/chide n f/73620	Topical	6-8 hours	24 hours	17 hours	72 hours	Consult pain specialist for conversions	Useful when PO route not available. Is lipophilic, requires some subcutaneous fat for proper absorption.	\$\$
HYDROcodone (in Vicodin®, Lortab® elixir)	http://online.le							Must watch preparations and avoid exceeding maximum acetaminophen doses.	\$\$ (oral tablets)
NOTE: some formulations contain acetaminophen	s <u>n f/73669</u>	10-20 minute s	2 hours	3.8-4.5 hours	3-6 hours	1	Available as extended release capsule and tablet outpatient	\$\$\$ (oral solution)	
HYDROmorphone	http://online.le xi.com/lco/acti on/doc/retriev	PO	15-30 minute s	30-90 minut es	1-3 hours	4-5 hours	4	Very potent opioid, with fewer reported side effects than morphine sulfate or oxycodone. Abuse deterrent formulation available: Exalgo®	\$\$
	e/docid/chide n_f/73673	IV	2-5 minute s	15-30 minut es	2.5 hours	4-5 hours			



CLINICAL P	AINWAI					Children's Hospital Colorado				
Drug	Dosing/ Dosage Forms	Route	Onset	Peak Effect	Half-life	Duration	Morphine Equivalent Dose (MED) Conversion Factor*	Comments	Estimated cash price at Walgreens (2016)	
	http://online.le xi.com/lco/acti	PO	30-60 minute s	2-4 hours	~23 hours	6-8 hours (22-48 hours with repeat dosing)	Consult pain specialist for conversions	QTc prolongation at higher doses. Multiple	\$	
methadone	on/doc/retriev e/docid/chide n f/73750	IV	10-20 minute s	1-2 hours	~23 hours	6-8 hours (22-48 hours				
http://u			15-	15-60	1	Neonates: 7-8 hours + 1-3 months: 6 hours			Used as the standard comparison for all opioid analgesics	\$\$
	http://online.le		IR minute s	hour	6 mo-2.5 years: 3hours 3-19 years: 1-2 hours Adults: 2-4 hours	3-5 hours	1	Caution in renal failure	(IR oral tablets and solution)	
morphine	xi.com/lco/acti on/doc/retriev e/docid/chide							Long-acting, available generically		
	n_f/2948023		R 1-2 hours	3-4 hours		8-12 hours	1	Covered by CO Medicaid (see notes at bottom of table for formulary link)	\$	
								Abuse deterrent formulation: Embeda® capsule		
		IV	2-10 minute s	20 minut es		2-4 hours				
		IT	5-10 minute s	1 hour		12-24 hours		NOTE: peak respiratory depression 2-3 hours		

Drug	Dosing/	Route	Onset	Peak	Half-life	Duration	Morphine	Comments	Estimated
Brug	Dosage	Route	Oliset	Effect	nun-me	Buration	Equivalent	Comments	cash price at



Pricing Legend (numbers estimated for a 50kg patient for a 7-day supply)

\$ = \$0 - \$20

\$\$ = \$21 - \$50

\$ = greater than \$50

NOTES:

- Codeine is no longer recommended for pain management in pediatric patients per the updated FDA warning. It was removed from CHCO formulary in 2012: FDA Drug Safety Communication
- Colorado Medicaid update on opioid prescribing regarding day supply: Opioid Policy Update FAQs for Medicaid Members •
- Colorado Medicaid formulary: CO Medicaid Formulary •



APPENDIX B. THE CRAFFT SCREENING INTERVIEW (VERSION 2.0)

The CRAFFT Interview (version 2.0)

Begin: "I'm going to ask you a few questions that I ask all my patients. Please be honest. I will keep your answers confidential."

	art A		
Du	ring the PAST 12 MONTHS, on how many days did you:		_
1.	Drink more than a few sips of beer, wine, or any drink containing alcohol? Say "0" if none.	# of days	
2.	Use any marijuana (pot, weed, hash, or in foods) or "synthetic marijuana" (like "K2" or "Spice")? Say "0" if none.	# of days	
3.	Use anything else to get high (like other illegal drugs, prescription or over-the-counter medications, and things that you sniff or "huff")? Say "0" if none.	# of days	
	Did the patient answer "0" for all questions in Part A	?	
	Yes 🗌 No 🗌		
	↓ ↓		
	Ask CAR question only, then stop Ask all six CRAFFT* qu	estions	below
Pa	ert B	No	Yes
	Have you ever ridden in a CAR driven by someone (including yourself) who was "high" or had been using drugs		
R	Do you ever use alcohol or drugs to RELAX , feel better about yourself, or fit in?		
Α	Do you ever use alcohol or drugs while you are by yourself, or ALONE?		
F	Do you ever FORGET things you did while using alcohol or drugs?		
F	Do your FAMILY or FRIENDS ever tell you that you should cut down on your drinking or drug use?		
т	Have you ever gotten into TROUBLE while you were using alcohol or drugs?		


*Two or more YES answers suggest a serious problem and need for further assessment. See back for further instructions -

NOTICE TO CLINIC STAFF AND MEDICAL RECORDS:

The information on this page is protected by special federal confidentiality rules (42 CFR Part 2), which prohibit disclosure of this information unless authorized by specific written consent. A general authorization for release of medical information is NOT sufficient.



1. Show your patient his/her score on this graph and discuss level of risk for a substance use disorder.



Probability of a DSM-5 Substance Use Disorder by CRAFFT score*

*Data source: Mitchell SG, Kelly SM, Gryczynski J, Myers CP, O'Grady KE, Kirk AS, & Schwartz RP. (2014). The CRAFFT cut-points and DSM-5 criteria for alcohol and other drugs: a reevaluation and reexamination. Substance Abuse, 35(4), 376–80.

2. Use these talking points for brief counseling.

1. REVIEW screening results

For each "yes" response: "Can you tell me more about that?"

RECOMMEND not to use

"As your doctor (nurse/health care provider), my recommendation is not to use any alcohol, marijuana or other drug because they can: 1) Harm your developing brain; 2) Interfere with learning and memory, and 3) Put you in embarrassing or dangerous situations."



RIDING/DRIVING risk counseling

"Motor vehicle crashes are the leading cause of death for young people. I give all my patients the Contract for Life. Please take it home and discuss it with your parents/guardians to create a plan for safe rides home."



4. RESPONSE elicit self-motivational statements Non-users: "If someone asked you why you don't drink or use drugs, what would you say?" Users: "What would be some of the benefits of not using?"



REINFORCE self-efficacy

"I believe you have what it takes to keep alcohol and drugs from getting in the way of achieving your goals."

3. Give patient Contract for Life. Available at www.crafft.org/contract

© John R. Knight, MD, Boston Children's Hospital, 2016. Reproduced with permission from the Center for Adolescent Substance Abuse Research (CeASAR), Boston Children's Hospital.

For more information and versions in other languages, see www.ceasar.org.



APPENDIX C. COLORADO PRESCRIPTION DRUG MONITORING PROGRAM LOGIN INFORMATION

ARE YOU PRESCRIBING OPIOID ANALGESICS?

Consider using the Colorado Prescription Drug Monitoring Program (PDMP)

Available to Colorado licensed individuals including: Physicians, Dentists, PAs, NPs, Pharmacists, and Resident/Fellow Physicians

Colorado law <u>REQUIRES</u> providers to check the PDMP prior to writing an outpatient refill or second opioid prescription (exceptions: chronic pain, cancer, hospice, palliative care, post-surgical pain anticipated to last more than 14 days).

Information from the PDMP will provide information to help guide appropriate prescribing and dispensing.

To access, visit this website: https://www.colorado.gov/dora-pdmp

*IF YOU HAVE NEVER LOGGED INTO THE SYSTEM, SELECT "PRESCRIBER/DISPENSER NEW REGISTRATION"

PLEASE REFER TO THE COLORADO PDMP USER SUPPORT MANUAL FOR MORE INFORMATION ABOUT REGISTERING AND ACCESSING THE SYSTEM.



APPENDIX D. SUBSTANCE ABUSE RESOURCES

Addition Research and Treatment Services (ARTS), Synergy Adolescent Treatment Services - Department of Psychiatry University of Colorado Anschutz Medical Campus

Referrals for Residential and Outpatient Services Lindsey Berman (303) 282-2603 Lindsey.Berman@ucdenver.edu

Director, Synergy Adolescent Treatment Services Irene Arguelles, LPC, CAC III (720) 283-3620 Irene.Arguelles@ucdenver.edu

<u>The Substance Abuse Treatment Education and Prevention (STEP) Program</u> - Denver Health Rose Medina (303) 602-1893 <u>RoseMarie.Medina@dhha.org</u>

Sandstone Care- Denver, Broomfield/Boulder

Substance abuse disorders and co-occurring disorders for adolescent Day Treatment, Intensive Outpatient, and General Outpatient

Phone: (303) 223-6404

Substance Use Intensive Outpatient Program - Porter Adventist Hospital

Clients are expected to attend group every week for 12 weeks.

- Monday 6-9 p.m. DBT Skills Group
- o Wednesday 6-9 p.m. 12-Step Group
- o Thursday 6-9 p.m. Process/Therapy Group

Phone: (303) 778-2541

ENCOMPASS: Integrated Treatment for Adolescents and Young Adults - University Hospital and Children's Hospital Colorado

Dr. Paula Riggs <u>Paula.riggs@ucdenver.edu</u> or 303-724-2235



CLINICAL IMPROVEMENT TEAM MEMBERS

Jenny Reese, MD | Hospital Medicine Alan Bielsky, MD | Anesthesiology George Sam Wang, MD | Emergency Medicine, Medical Toxicology Leigh Anne Bakel, MD | Hospital Medicine Ashley Reid, PharmD | Clinical Pharmacist Sheryl Kent, PhD | Anesthesiology/Pain Management Services Jan Grantham, MS, RN-BC, PCNS-BC | Anesthesiology/Pain Management Services Kristin Kalita, MD | Pediatric Resident Benjamin Bernier, MSN, CCRN | Accreditation Jeffery Galinkin, MD | Anesthesiology Amy Poppy, PharmD | Patient Safety Katherine Chin, DDS | Dentistry Angela Swanson, MS | Clinical Effectiveness Tod Bos | Clinical Effectiveness Sarah Nickels, PhD, MSW | Clinical Effectiveness

REVIEWED BY THE FOLLOWING EXPERTS

Mike DiStefano, MD | Director of Clinical Operations, Emergency Medicine Kevin Carney, MD | Medical Director, Anschutz Emergency Department Jennifer Bruny, MD | Pediatric Surgery David Brumbaugh, MD | Gastroenterology Norman Friedman, MD | Otolaryngology Kenny Chan, MD | Otolaryngology Ada Koch, PharmD | Otolaryngology Ada Koch, PharmD | Clinical Pharmacy Services Julie Wilson, MD | Sports Medicine/Orthopedics Nathan Donaldson, MD | Orthopedics Institute Jason Rhodes, MD | Orthopedics Institute Heidi McNeely, MSN, RN, PCNS-BC | Innovations & Outcomes Melisha Hanna, MD | Kidney Center

APPROVED BY

Pharmacy & Therapeutics Committee – October 5, 2017; ED ALTO updates reviewed on 12/5/19 Clinical Pathways and Measures Committee – October 17, 2017; revised July 31, 2018

MANUAL/DEPARTMENT	Clinical Care Guidelines/Quality
ORIGINATION DATE	October 17, 2017
LAST DATE OF REVIEW OR REVISION	July 31, 2018



APPROVED BY

huns

Lalit Bajaj, MD Medical Director, Clinical Effectiveness

REVIEW | REVISION SCHEDULE

Scheduled for full review on July 31, 2022.

Clinical pathways are intended for informational purposes only. They are current at the date of publication and are reviewed on a regular basis to align with the best available evidence. Some information and links may not be available to external viewers. External viewers are encouraged to consult other available sources if needed to confirm and supplement the content presented in the clinical pathways. Clinical pathways are not intended to take the place of a physician's or other health care provider's advice, and is not intended to diagnose, treat, cure or prevent any disease or other medical condition. The information should not be used in place of a visit, call, consultation or advice of a physician or other health care provider. Furthermore, the information is provided for use solely at your own risk. CHCO accepts no liability for the content, or for the consequences of any actions taken on the basis of the information provided. The information provided to you and the actions taken thereof are provided on an "as is" basis without any warranty of any kind, express or implied, from CHCO. CHCO declares no affiliation, sponsorship, nor any partnerships with any listed organization, or its respective directors, officers, employees, agents, contractors, affiliates, and representatives.

Discrimination is Against the Law. Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Children's Hospital Colorado does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

Children's Hospital Colorado provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters, written information in other formats (large print, audio, accessible electronic formats, other formats). Children's Hospital Colorado provides free language services to people whose primary language is not English, such as: Qualified interpreters, information written in other languages.

If you need these services, contact the Medical Interpreters Department at 720.777.9800.

If you believe that Children's Hospital Colorado has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Corporate Compliance Officer, 13123 E 16th Avenue, B450, Aurora, Colorado 80045, Phone: 720.777.1234, Fax: 720.777.7257, corporate. compliance@childrenscolorado.org. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Corporate Compliance Officer is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 1-800-368-1019, 800-537-7697 (TDD) Complaint forms are available at www.hhs.gov/ocr/office/file/index.html.

Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-720-777-9800.

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-720-777-9800.

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1-720-777-9800 번으로 전화해 주십시오

注意:如果您使用繁體中文,您可以免費獲得語言援助服務。請致電1-720-777-9800。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1-720-777-9800.

ማስታወሻ: የሚና7ሩት ቋንቋ ኣማርኛ ከሆነ የትርፖም እርዳታ ድርጅቶች፣ በነጻ ሊያፖዝዎት ተዘጋጀተዋል፡ ወደ ሚከተለው ቁጥር ይደውሉ 1-720-777-9800 (መስማት ለተሳናቸው.

. ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 1-9800-777 (رقم

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1-720-777-9800.

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1-720-777-9800.

ध्यान बनु होस:्तपाइले नेपाल बोल्नहन्छ भन तपाइको निम्त भाषा सहायता सवाहरू नःशल्क रूपमा उपलब्ध छ । फोन गनु होसर् 1-720-777-9800 ।

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1-720-777-9800.

注意事項:日本語を話される場合、無料の言語支援をご利用いただけます。1-720-777-9800まで、お電話にてご連絡ください。

Ntị: Q bụrụ na asụ Ibo, asụsụ aka ọasụ n'efu, defu, aka. Call 1-720-777-9800.